EFFICACY OF ZOLEDRONIC ACID IN PATIENTS WITH RENAL CANCER METASTATIC TO BONE

Risultato della ricerca: Otherpeer review

Abstract

I in renal cancer patients probably related to survival increase. There are few data in literature about the role of BPs in the treat- ment of bone disease from colorectal cancer. We present the pre- liminary data of a large Italian multicenter retrospective analysis.Methods. 284 renal cancer patients with evidence of bone metastases have been included in the study at the moment of ab- stract submission. Patients characteristics, skeletal related events (SRE) data and median survival after bone metastases appear- ance have been collected in a master data base and statistically analyzed. The primary efficacy endpoint was time to first SRE; secondary endpoint was median survival.Results. A total of 284 patients have been included for zole- dronic efficacy analysis. A total of 130 patients received zole- dronic acid (4 mg) via a 15-minute infusion every 4 weeks until performance status worsening or death. 154 patients have been analysed as control group. The median time to first SRE in the whole population was 1 month (0-72). The median time to first SRE in the zoledronic treated patients was 3 months (0-101) compared with 1 month (0-22) in the control group (p <0.05). The median survival after skeletal progression was 12 (1-178). The median survival in the zoledronic treated group was 15 months (2-120) compared with 7 months (1-178). (p <0.05). On- ly 2 cases of ONJ have been diagnosed.Conclusions. Complete results of statistical analysis will be presented during the meeting. The present analysis represents a confirmation, in clinical practice scenario, of zoledronic acid ac- tivity in bone metastases in renal cancer patients.
Lingua originaleEnglish
Pagine130-131
Numero di pagine2
Stato di pubblicazionePublished - 2011

Fingerprint Entra nei temi di ricerca di 'EFFICACY OF ZOLEDRONIC ACID IN PATIENTS WITH RENAL CANCER METASTATIC TO BONE'. Insieme formano una fingerprint unica.

Cita questo